– USA, WA – Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company today announced the appointment of Dr. Jörn Drappa (MD, Ph.D.) to its Board of Directors.
“We are very pleased to welcome Dr. Drappa to our Board of Directors. Jörn brings a tremendous depth of experience leading the successful development of immunology drugs across both small biotech and large pharmaceutical companies, and from early stage through commercialization. As a biotech executive with a proven track record and a board-certified internist and rheumatologist, Jörn will bring a unique perspective to our Board and provide valuable guidance as we continue to advance multiple clinical programs, including ALPN-303, a potentially best-in-class dual B-cell cytokine antagonist of BAFF and APRIL being developed for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases,” said Executive Chairman and CEO, Dr. Mitchell Gold,.
Concurrently, the company also announced that Dr. Jay Venkatesan has stepped down from the Board.
About Dr. Jörn Drappa
Dr. Drappa most recently served as CMO of Ventyx Biosciences. Before Ventyx, Dr. Drappa co-founded Viela Bio, a biotechnology company focused on the discovery, development, and commercialization of treatments for autoimmune and severe inflammatory diseases, and served as its Head of R&D and CMO through its acquisition by Horizon Therapeutics in March 2021 for $3.1 billion. At Viela Bio, Dr. Drappa led the development of UPLIZNA (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of Neuromyelitis Optica Spectrum Disorder. Before Viela Bio, he held various roles of increasing responsibility leading clinical development programs at MedImmune/AstraZeneca, Genentech/Roche, and Amgen.
Dr. Drappa said, “Using their proprietary directed evolution platform, Alpine has rapidly developed multiple novel and differentiated multi-targeted immunotherapies with the potential to improve outcomes for patients suffering from serious diseases. Alpine is approaching several key catalysts. I am excited to join with the other Board members to help the team further advance their clinical pipeline across oncology and autoimmune and inflammatory indications.”
Dr. Drappa received his medical and Ph.D. degrees from the University of Cologne in Germany. He completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in rheumatology at the Hospital for Special Surgery, NY.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine seeks to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.
For more information : https://www.alpineimmunesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
